Global Acinetobacter Pneumonia Therapeutics: An Overview Current Therapeutic Strategies and Challenges

Global Acinetobacter Pneumonia Therapeutics

Acinetobacter baumannii is an opportunistic pathogen that causes various types of nosocomial infections including pneumonia, bacteremia, wound and surgical site infections. Due to its increasing antibiotic resistance, Acinetobacter pneumonia has emerged as a serious threat in hospitals across the world. This Gram-negative bacterium survives for long periods on hospital surfaces and is readily transmitted between patients via the hands of healthcare workers. While carbapenem antibiotics were once effective treatments, the emergence and global spread of carbapenem-resistant A. baumannii (CRAB) strains has challenged clinicians. This article discusses the current therapeutic strategies and challenges in managing Acinetobacter pneumonia globally.

Multi-Drug Resistant Strains Pose Serious Risk

The World Health Organization has classified CRAB as a critical priority pathogen due to the very limited treatment options. Multi-drug and pan-drug resistant Global Acinetobacter Pneumonia Therapeutics infections that do not respond even to colistin are increasingly being reported worldwide. Such resistant strains pose serious risks, especially in severely ill patients in intensive care units who are vulnerable to drug-resistant infections. Mortality rates as high as 50% have been observed in cases of CRAB ventilator-associated pneumonia and bacteremia. The ability of A. baumannii to survive for prolonged periods in hospitals on dry surfaces and adopt multidrug tolerance enhances its nosocomial spread. Effective infection control strategies combined with judicious antibiotic use are crucial to curb the emergence and transmission of highly resistant strains.

Off-Label Antibiotics Used as Last Resort

In the absence of new antibiotic approvals, clinicians are compelled to use older or off-label drugs as a last resort to treat CRAB and pandrug-resistant Acinetobacter infections. Polymyxins such as colistin and polymyxin B, which were rediscovered and introduced in the 1950s, have regained significance due to lack of newer treatment options. However, colistin resistance has started emerging among Acinetobacter strains worldwide. Other agents used off-label include tigecycline, fosfomycin, aminoglycosides and rifampicin alone or in combinations. Data on the clinical efficacy of these therapies is limited since they have not been approved for specific Acinetobacter infections. Combination therapies, while having a theoretical advantage, require well-designed clinical trials to prove benefits and safety profiles.

Clinical Research On New Agents and Combinations

Several pharmaceutical companies and academic research groups are investing efforts to develop novel drugs active against CRAB and pandrug-resistant strains. Early phase clinical trials are ongoing to evaluate new agents such as eravacycline, plazomicin and cefiderocol for treating serious Acinetobacter infections. Combination therapies are also being studied to prevent or delay resistance development. For instance, a Phase 3 trial evaluated the efficacy and safety of eravacycline plus meropenem versus meropenem alone in hospitalized adults with complicated intra-abdominal infections, including those caused by CRAB. Results showed non-inferiority of the combination, paving way for its potential approval to treat infections by these organisms. Several other antibiotic combinations are in preclinical and early phase studies against CRAB infections. Well-powered randomized controlled studies are needed to establish the role of new agents and optimal combination regimens in treating Acinetobacter pneumonia therapeutics.

Alternative Therapeutic Approaches

Besides antibiotics, research is ongoing into alternate therapeutic approaches such as phage therapy, antimicrobial peptides, inhaled agents, and vaccines against Acinetobacter. Bacteriophages (viruses that infect and lyse bacteria) have shown promise against topically applied CRAB infections in case reports and small clinical studies. However, their efficacy as systemic agents for pneumonia is still unproven. Synthetic antimicrobial peptides that can directly kill Acinetobacter in vitro without inducing resistance are in preclinical testing. Some may work synergistically with antibiotics. Early phase trials are also assessing the potential of inhaled colistin and liposomal amikacin for the treatment of ventilator-associated pneumonia caused by MDR Gram-negative bugs including Acinetobacter. Though challenging, an effective vaccine against CRAB could aid in control and prevention of outbreaks in high-risk settings. Further studies are warranted to evaluate these approaches and establish their roles as standalone or adjunctive therapies for Acinetobacter pneumonia.

Challenges in Low-and-Middle Income Nations

Access to appropriate antibiotics poses a significant challenge in resource-constrained healthcare systems of many low-and-middle income countries where rates of drug-resistant A. baumannii pneumonia are among the highest globally. Unregulated antibiotic use, lack of infection control practices and overcrowding in hospitals have contributed to the emergence and dissemination of highly resistant clones in these settings. Economic barriers restrict optimal use of newer and more effective agents. Off-patent drugs like polymyxins tend to be used long after their efficacy declines due to resistance, leading to therapeutic failures. Development of rapid, inexpensive and accurate diagnostic tests suitable for field use would aid scale-up of appropriate antibiotic stewardship and treatment programs in such countries. Strengthening hospital infection prevention practices through hygiene training and engineered solutions can play a major role in curbing the nosocomial spread of problematic pathogens like CRAB. Regional and international collaborations are important to enable equitable access to diagnostic tools and optimize antibiotic use globally to fight the rising tide of antimicrobial resistance.

Get more insights on Global Acinetobacter Pneumonia Therapeutics